In a research report released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharmaceuticals (LGND) with a $92 price target, following today’s news that LGND’s partner …
In a research report released July 18, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Rexahn Pharmaceuticals (RNN) with a $3 price target, …
On Friday, Regeneron Pharmaceuticals (REGN) announced results from the Phase III VIVID-DME study of Eylea in DME that showed that treatment with Eylea 2 mg dosed …
In a report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharmaceutical (LGND) with a $92.00 price target, following LGND’s announcemet that total revenue for 2Q14 …
In a research note released today, Roth Capital analyst Joseph Pantginis reiterated coverage with a Buy rating on shares of Peregrine Pharmaceuticals, Inc. (PPHM) and a $5 price target.
In a research report published yesterday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Cytokinetics Inc. (CYTK) with a $13 price …
In a research note released today, Roth Capital analyst Joseph Pantginis reiterated coverage with a Buy rating on shares of Regeneron Pharmaceuticals (REGN) and a $382 price target, after REGN and partner …
In a research report released this morning, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Lion Biotechnologies Inc. (LBIO) with a $20 …
In a research note released yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Concert Pharmaceuticals Inc. (CNCE) with a $28.
In a research note released yesterday, Roth Capital analyst Joseph Pantginis maintained coverage with a Buy rating on shares of Cytori Therapeutics (CYTX), and a price target of $10, following yesterday’s …
